Patient Age Is Not a Determinant of 12-Month Pain Response After Autologous Adipose-Derived Stromal Vascular Fraction Injection for Knee Osteoarthritis.
Kim YS., Koh YG.
Retrospective Study with a reported sample of 357 on Knee Osteoarthritis, Osteoarthritis, published in Medicina (Kaunas) (2026) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Retrospective Study
- Journal
- Medicina (Kaunas) (2026)
- Country
- Switzerland
- Reported sample size
- 357
- Source database
- PubMed
- PMID
- 42356058
- DOI
- 10.3390/medicina62061044
Abstract (original English)
Background: Autologous adipose-derived stromal vascular fraction (SVF) is increasingly used for symptomatic knee osteoarthritis (OA), but it remains uncertain whether patient age should influence candidacy. We examined whether age was related to 12-month pain response after intra-articular SVF administration. Methods: This retrospective knee-level analysis included 357 knees from 266 patients with Kellgren-Lawrence grade II-IV OA treated with adipose-derived SVF and followed for at least 12 months. Pain was assessed with the visual analog scale (VAS). Group comparisons and Spearman correlation analyses were used to explore relationships between age, baseline variables, injected cell number, and pain outcomes. Results: VAS scores improved from 6.5 ± 1.2 before treatment to 3.1 ± 1.6 at final assessment ( p < 0.01). Age did not show a significant association with baseline pain ( p = 0.128), final pain ( p = 0.088), or measured baseline factors. Higher body mass index, more severe radiographic OA, and lower SVF cell number were associated with less favorable final pain scores. No serious treatment-related adverse event was identified. Conclusions: SVF injection was followed by significant pain reduction at 12 months. In this cohort, chronological age was not a meaningful determinant of response, whereas metabolic burden, structural OA severity, and delivered cell dose were more re
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • Without an adequate control group, treatment effects cannot be separated from other factors.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level AMeta-analysisPubMed
Clinical Outcomes of Biologic Therapies for Knee Osteoarthritis: A Systematic Review and Meta-analysis of Studies With ≥12-Month Follow-up.
Meta-analysis on Knee Osteoarthritis, Osteoarthritis, published in Mod Rheumatol (2026) — summary generated from the PubMed abstract.
- 2026
Mod Rheumatol - Level AMeta-analysisEurope PMC
Towards optimized rehabilitation with regenerative therapy: A systematic review and meta-analysis on the effects of cell-based injections for knee osteoarthritis
Meta-analysis on Knee Osteoarthritis, Osteoarthritis, published in Knee Surg Sports Traumatol Arthrosc (2026) — summary generated from the PubMed abstract.
- 2026
Knee Surg Sports Traumatol Arthrosc - Level ASystematic ReviewPubMed
Intra-articular fat grafting for pain relief and functioning improvement in patients with knee osteoarthritis: systematic review.
Systematic Review on Knee Osteoarthritis, Osteoarthritis, published in Disabil Rehabil (2026) — summary generated from the PubMed abstract.
- 2026
Disabil Rehabil - Level ASystematic ReviewPubMed
Research Landscape of Stem Cell Applications in Musculoskeletal Tissue: A Scoping Review.
Systematic Review on Knee Osteoarthritis, Osteoarthritis, published in Cells (2026) — summary generated from the PubMed abstract.
- 2026
Cells - Level AMeta-analysisPubMed
Comparative efficacy of different doses of mesenchymal stem cells derived from different tissue sources for knee osteoarthritis: a systematic review and network meta-analysis of randomized controlled trials.
Meta-analysis with a reported sample of 602 on Knee Osteoarthritis, Osteoarthritis, Chronic Inflammation, Immune Modulation, published in PeerJ (2026) — summary generated from the PubMed abstract.
- 2026
- n = 602
PeerJ - Level AMeta-analysisEurope PMC
Influence of platelet-rich plasma composition on pain and functional performance in knee osteoarthritis: a systematic review and network meta-analysis
Meta-analysis with a reported sample of 5251 on Knee Osteoarthritis, Osteoarthritis, published in Knee Surg Relat Res (2026) — summary generated from the PubMed abstract.
- 2026
- n = 5251
Knee Surg Relat Res